Henderson Michael X, Chung Charlotte Hiu-Yan, Riddle Dawn M, Zhang Bin, Gathagan Ronald J, Seeholzer Steven H, Trojanowski John Q, Lee Virginia M Y
Department of Pathology and Laboratory Medicine, Institute on Aging and Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, and.
Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania 19104.
J Neurosci. 2017 Jun 14;37(24):5870-5884. doi: 10.1523/JNEUROSCI.2705-16.2017. Epub 2017 May 18.
Parkinson's disease (PD) patients progressively accumulate intracytoplasmic inclusions formed by misfolded α-synuclein known as Lewy bodies (LBs). LBs also contain other proteins that may or may not be relevant in the disease process. To identify proteins involved early in LB formation, we performed proteomic analysis of insoluble proteins in a primary neuron culture model of α-synuclein pathology. We identified proteins previously found in authentic LBs in PD as well as several novel proteins, including the microtubule affinity-regulating kinase 1 (MARK1), one of the most enriched proteins in this model of LB formation. Activated MARK proteins (MARKs) accumulated in LB-like inclusions in this cell-based model as well as in a mouse model of LB disease and in LBs of postmortem synucleinopathy brains. Inhibition of MARKs dramatically exacerbated α-synuclein pathology. These findings implicate MARKs early in synucleinopathy pathogenesis and as potential therapeutic drug targets. Neurodegenerative diseases are diagnosed definitively only in postmortem brains by the presence of key misfolded and aggregated disease proteins, but cellular processes leading to accumulation of these proteins have not been well elucidated. Parkinson's disease (PD) patients accumulate misfolded α-synuclein in LBs, the diagnostic signatures of PD. Here, unbiased mass spectrometry was used to identify the microtubule affinity-regulating kinase family (MARKs) as activated and insoluble in a neuronal culture PD model. Aberrant activation of MARKs was also found in a PD mouse model and in postmortem PD brains. Further, inhibition of MARKs led to increased pathological α-synuclein burden. We conclude that MARKs play a role in PD pathogenesis.
帕金森病(PD)患者会逐渐积累由错误折叠的α-突触核蛋白形成的胞质内包涵体,即路易小体(LBs)。路易小体还包含其他蛋白质,这些蛋白质在疾病过程中可能相关也可能不相关。为了鉴定在路易小体形成早期涉及的蛋白质,我们在α-突触核蛋白病理学的原代神经元培养模型中对不溶性蛋白质进行了蛋白质组学分析。我们鉴定出了先前在PD患者真实的路易小体中发现的蛋白质以及几种新蛋白质,包括微管亲和力调节激酶1(MARK1),它是该路易小体形成模型中含量最丰富的蛋白质之一。活化的MARK蛋白(MARKs)在这个基于细胞的模型中的路易小体样包涵体中积累,也在路易小体疾病的小鼠模型以及死后突触核蛋白病大脑的路易小体中积累。抑制MARKs会显著加剧α-突触核蛋白病理学变化。这些发现表明MARKs在突触核蛋白病发病机制早期起作用,并且是潜在的治疗药物靶点。神经退行性疾病只有在死后大脑中通过关键的错误折叠和聚集的疾病蛋白的存在才能明确诊断,但导致这些蛋白质积累的细胞过程尚未得到很好的阐明。帕金森病(PD)患者在路易小体中积累错误折叠的α-突触核蛋白,这是PD的诊断特征。在这里,通过无偏差质谱法鉴定出微管亲和力调节激酶家族(MARKs)在神经元培养的PD模型中被激活且不溶。在PD小鼠模型和死后的PD大脑中也发现了MARKMARKs异常激活。此外,抑制MARKs导致病理性α-突触核蛋白负担增加。我们得出结论,MARKs在PD发病机制中起作用。